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ABSTRACT	
Background		
Much	has	been	studied	in	regard	to	non-prescription	medicines	(NPMs),	but	the	impact	of	
greater	emphasis	toward	patient	self-selection	of	such	agents	is	still	not	well	understood,	
and	evidence	in	the	literature	might	be	equivocal.		
Objective		
The	aim	was	to	examine	whether	or	not	pharmacist	interventions	are	important	in	the	sale	
of	NPMs	and	to	summarize	the	evidence	of	pharmacists'	contribution	in	maintaining	patient	
safety	and	improving	the	quality	of	consultations	involving	NPMs.	
Methods		
Seven	online	databases	were	searched	to	identify	the	literature	on	studies	conducted	within	
the	UK	and	in	countries	comparable	to	the	UK	reporting	on	consultations	and	selling	of	
NPMs	published	between	1980	and	2013.	All	study	designs	except	for	quantitative	surveys	
were	eligible	for	inclusion	into	the	review.	The	data	extraction	and	quality	assessment	were	
performed	according	to	the	National	Institute	for	Health	and	Care	Excellence	guidelines.	The	
data	extracted	from	the	studies	were	analyzed	and	presented	qualitatively.	
Results		
Eighty-three	studies	from	an	original	12,879	citations	were	included	in	this	review.	Just	
under	half	of	the	studies	were	published	between	2000	and	2009	(n	=	38;	46%).	Thirty-three	
(44%)	of	the	studies	were	conducted	in	the	UK.	The	review	showed	that	in	terms	of	the	
contribution	of	community	pharmacy	staff	in	consultations	for	NPMs,	non-pharmacist	staff	
dealt	with	a	large	proportion	of	the	consultations	and	pharmacists	were	usually	involved	in	
the	consultation	through	referral	from	non-pharmacist	staff	member.	Counseling	was	not	
consistently	offered	to	everyone.	Where	counseling	was	provided	it	was	not	always	of	
sufficient	quality.	Consultations	were	performed	much	better	when	symptoms	were	
presented	compared	to	when	people	made	a	direct	product	request.	Pharmacists	were	
reported	to	conduct	better	consultations	than	non-pharmacist	staff.	There	was	evidence	to	
suggest	that	where	counseling	was	appropriately	provided	this	afforded	the	person	a	safe	
environment	to	utilize	their	NPMs.	
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Conclusions		
Seeking	methods	to	develop	better	engagement	with	customers	accessing	pharmacy	
services	for	NPMs	is	necessary	to	enhance	the	interaction	between	these	two	parties.	
Efforts	to	enhance	the	community	pharmacy	environment	to	bring	about	a	more	positive	
experience	for	people	using	pharmacy	is	needed	at	present	and	will	be	important	if	the	
model	for	the	selection	of	NPMs	is	modified	in	the	UK.	More	studies	are	needed	to	allow	a	
better	understanding	of	the	impact	self-selection	may	have	on	patient	safety	in	the	
community	pharmacy	context.		
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1. INTRODUCTION	/	BACKGROUND	
The	law	surrounding	supply	of	non-prescription	medicines	(NPMs)	varies	from	country	
to	country.	In	Australia	and	New	Zealand	there	is	a	pharmacist	category	of	NPMs	(S3)	
that	can	only	be	supplied	with	the	intervention	of	and	counseling	from	a	pharmacist.	In	
the	US,	NPMs	are	freely	available	for	self-selection	on	open	shelves	and	in	large	
quantities.	In	much	of	Europe	medicines	may	only	be	sold	from	a	pharmacy.	Finland	all	
counseling	about	NPMs	must	be	given	by	a	pharmacist.	Under	the	current	United	
Kingdom	(UK)	law,	there	are	two	categories	of	NPMs:	General	sales	list	medicines	and	
pharmacy	medicines	(P),	where	supply	of	P	medicines	is	only	permissible	only	under	
supervision	of	a	pharmacist.	Various	stakeholders,	including	the	General	Pharmaceutical	
Council	(GPhC)	are	examining	a	proposal	to	permit	self-selection	of	P	medicines	in	UK	
community	pharmacies.	One	key	feature	this	decision	hinges	on	is	the	assurance	that	
patient	safety	will	not	be	compromised	by	this	proposed	change	which	is	likely	to	result	
in	a	large	number	of	currently	available	P	medicines	being	sold	without	the	opportunity	
for	a	pharmacist	to	intervene.	To	gain	an	understanding	of	the	possible	impact	this	wider	
availability	of	P	medicines	may	have	in	UK	community	pharmacies,	a	review	of	studies	
examining	the	current	role	that	pharmacists	play	when	undertaking	consultations	of	
NPMs	was	undertaken.	The	overarching	aim	of	this	review	was	to	examine	whether	or	
not	pharmacist	interventions	are	important	in	the	sale	of	NPMs	and	to	summarize	the	
evidence	of	pharmacists'	contribution	in	maintaining	patient	safety	and	improving	the	
quality	of	consultations	involving	NPMs.	Implicit	in	these	aims	is	the	need	to	examine	
non-pharmacist	staff	roles	in	supply	of	NPMs.	A	secondary	aim	of	this	review	was	to	
identify	the	future	research	agenda.		
	
The	sale	and	supply	of	medicines	in	the	United	Kingdom	(UK)	is	regulated	by	the	
Medicines	Act	1986.1	This	act	defines	three	medicine	categories	each	with	their	own	
restrictions	regarding	the	sale	and	supply	of	these	medicines.	Prescription-only	
medicines	(POMs)	can	only	be	obtained	from	a	pharmacy	or	a	dispensing	general	
practice	surgery	with	a	legal	prescription	written	by	a	general	practitioner	or	other	
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suitably	qualified	health	care	professional.2	Pharmacy	(P)	medicines	are	available	
without	prescription	but	may	only	be	sold	from	a	registered	pharmacy	premise	and	the	
sale	should	be	supervised	by	a	pharmacist.	The	last	group	is	the	medicines	on	the	
general	sales	list	(GSL).	GSL	medicines	can	be	bought	without	a	prescription	and	are	
available	in	any	retail	outlet.1	Most	of	the	new	medicines	entering	the	market	start	as	
POM,	but	after	a	few	years	a	medicine	may	be	reclassified	(deregulated).	Reclassification	
is	normally	requested	by	the	company	that	holds	the	marketing	authorization,	but	could	
also	be	initiated	by	other	interested	parties,	for	example,	the	professional	body	or	
community	pharmacy	chains.	All	applications	concerning	reclassification	are	evaluated	
by	the	Medicines	and	Health	Products	Regulatory	Agency	(MHRA).	They	investigate	
whether	or	not	a	medicine	could	be	reclassified	according	to	several	criteria	included	in	
the	Human	Medicines	Regulations	2012,	regulation	62	(3)	(POM	to	P)	and	regulation	62	
(5)	(P	to	GSL).3		
	
Various	stakeholders,	including	the	General	Pharmaceutical	Council	(GPhC),	are	
examining	a	proposal	to	allow	self-selection	of	P	medicines	in	UK	pharmacies,	without	
the	supervision	of	a	pharmacist.4	This	move	is	being	deemed	necessary	to	allow	patients	
better/easier	access	to	medicines	for	the	management	of	minor	ailments.	One	key	
feature	this	decision	hinges	on	is	the	assurance	that	patient	safety	will	not	be	
compromised	by	this	proposed	change.5		
	
The	primary	aim	of	this	systematic	review	was	to	identify	and	summarize	the	available	
evidence	of	the	role	pharmacists	play	in	maintaining	and	guaranteeing	patient	safety	
and	improving	the	quality	of	consultations	for	supply	of	P	medicines,	and	to	establish	
whether	or	not	the	intervention	of	a	pharmacist	is	important	in	the	sale	of	P	medicines	
in	community	pharmacies.	A	secondary	aim	was	to	proffer	a	research	agenda	in	this	area	
of	pharmacy	practice.		
Methods		
Review	team	and	review	method		
This	systematic	review	is	reported	in	accordance	with	the	Preferred	Reporting	Items	for	
Systematic	Reviews	and	Meta-Analyses	(PRISMA)	statement.6		
The	review	team	consisted	of	the	main	reviewer	LvE,	NS	and	CA.	The	systematic	review	was	
undertaken	based	on	the	five-step	principle	of	conducting	a	systematic	review	as	described	
by	Khan	et	al,	which	includes	defining	the	research	question,	identifying	the	literature,	
quality	assessment	of	the	selected	literature,	summarizing	the	findings	and	interpreting	the	
evidence.7	In	this	review,	the	question	was	defined	by	the	Royal	Pharmaceutical	Society,	
and	hence	the	authors	entered	the	review	at	step	two	of	the	process.		
Literature	identification		
Databases	searched	and	search	strategy		
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A	multiple	database	search	spanning	33	years	(1980–2013)	was	performed	to	identify	
relevant	literature	for	inclusion	in	the	review	in	June	2013.	Databases	searched	included	
Embase,	International	Pharmaceutical	Abstracts	(IPA)	and	PsycInfo	(all	searched	via	OVID),	
SCOPUS,	Web	of	Science,	Cochrane,	Applied	Social	Sciences	Index	and	Abstracts	(ASSIA)	and	
Medline.		
A	list	of	Medical	Subject	Headings	(MeSH)	terms,	MeSH-like	terms	and	free	text	words	with	
wild	card	truncations	were	combined	to	develop	search	strategies	to	capture	the	
community	pharmacy	setting,	NPM	sales	and	condition	for	which	NPMs	are	currently	used.	
The	exact	terms	used	to	run	the	search	were	tailored	for	the	requirements	of	the	individual	
databases	(see	Table	1).	Searches	were	restricted	to	studies	published	either	in	English	or	in	
Dutch.		
Criteria	for	including	studies	in	the	review		
Included	studies	were	conducted	in	the	UK,	Ireland,	Australia	and	New	Zealand,	which	have	
a	similar	community	pharmacy	context	to	the	UK.	Studies	further	afield	from	other	
European	countries	and	North	America	were	scoped	to	gain	insight	into	the	realities	to	be	
considered	if	NPMs	are	made	available	for	self-selection.	All	titles	and	abstracts	for	articles	
retrieved	were	screened	for	relevance	against	the	inclusion/exclusion	criteria	listed	in	Table	
2	by	the	main	reviewer	(LvE).	A	second	reviewer	(NS)	screened	10%	of	these	to	verify	the	
selection	of	studies.	Full	articles	of	titles	and	abstracts	retained	at	this	stage	were	obtained	
for	further	reading.	In	the	second	round	of	the	review	the	main	reviewer	(LvE)	reviewed	all	
the	articles	for	relevance	whilst	the	other	two	reviewers	(CA	and	NS)	reviewed	two-thirds	of	
the	papers	each,	with	one-third	articles	overlapping.	During	this	second	round	of	the	review	
the	main	reviewer	(LvE)	also	searched	the	bibliographies	of	the	retrieved	articles	for	
additional	relevant	articles.	At	all	stages	of	the	review	disagreements	between	reviewers	
were	resolved	by	discussion.	
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		 Database	MeSH	term	 Map	Term/	Subject	Heading	 MeSH	term	
Keyword	 Medline/PubMed	 Embase	 Cochrane	
Pharmacist(s)	 Pharmacists	 Pharmacist	 Pharmacists	
Pharmacy/ies	 Pharmacies	 Pharmacy	 Pharmacies	
Community	pharmacy/ies	 Community	Pharmacy	Services	 Pharmacy	(community	pharmacy	
services	is	a	specific	term	within	
pharmacy)	
Community	Pharmacy	Services	
		 		 		 		
Non	prescription	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
Non	prescripton	medicine(s)	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
OTC	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
over	the	counter	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
OTC	medicine(s)	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
over	the	counter	medicine(s)	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
OTC	drug(s)	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
over	the	counter	drug(s)	 Nonprescription	drugs	 non	prescription	drug	 Nonprescription	drugs	
Pharmacist	only	drug(s)	 Behind-the-Counter	drugs	 Not	found	 Behind-the-Counter	drugs	
P-meds	 Behind-the-Counter	drugs	 Not	found	 Behind-the-Counter	drugs	
P-medicine(s)	 Behind-the-Counter	drugs	 Not	found	 Behind-the-Counter	drugs	
Pharmacy	meds	 Behind-the-Counter	drugs	 Not	found	 Behind-the-Counter	drugs	
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Pharmacy	medicine(s)	 Behind-the-Counter	drugs	 Not	found	 Behind-the-Counter	drugs	
Self	care	 Self	Care	(Very	broad,	includes	also	
blood	glucose	self	monitoring,	self	
administration	and	self	medication)	
Self	care		 Self	Care	(Very	broad,	includes	also	
blood	glucose	self	monitoring,	self	
administration	and	self	medication)	
Self	care	medication	 Not	found	 Not	found	 Not	found	
Self	care	medicine(s)	 Not	found	 Not	found	 Not	found	
Self	medication	 Self	Medication	 Self	medication	 Self	Medication	
Minor	ailment(s)	 Not	found	 Not	found	 Not	found	
Minor	illness	 Not	found	 Not	found	 Not	found	
	
Table	1:	Search	terms	used	to	identify	articles	for	review		
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Data	extraction		
Data	extraction	was	undertaken	by	the	main	reviewer	(LvE)	and	by	a	second	reviewer	(NS).	
The	data	extracted	by	the	main	reviewer	was	then	summarized	according	to	the	National	
Institute	for	Health	and	Clinical	Excellence	(NICE)	methods.8	Three	different	data	extraction	
forms	were	used	to	reflect	the	nature	of	the	study	designs	adopted	in	the	studies	being	
reviewed,	namely	qualitative,	quantitative	and	mixed	methods	study	designs.	
Questionnaires	were	included	only	if	they	we	part	of	a	larger	study.	The	data	extraction	
form	for	the	studies	with	a	mixed	method	design	was	constructed	by	combining	important	
points	from	the	qualitative	and	quantitative	tools.	The	suitability	of	the	templates	was	
confirmed	by	the	main	reviewer	(LvE)	running	a	test	data	extraction	exercise	on	each	of	the	
study	designs	in	discussion	with	the	other	two	reviewers.		
Quality	assessment		
The	quality	assessment	of	the	papers	included	in	the	review	was	performed	by	the	main	
reviewer	with	guidance	from	the	remaining	two	reviewers.	The	quality	assessment	
checklists	used	were	also	developed	from	the	NICE	method	mentioned	above.	To	provide	a	
method	of	comparing	quality	for	the	different	study	designs	percentages	of	adhering	with	
checklist	was	computed.	Every	item	of	the	checklist	was	judged	and	could	be	answered	
either	positively	or	negatively/unclear.	A	percentage	was	calculated	out	of	the	number	of	
positively	answered	questions	to	the	total	number	of	questions.	The	quality	ranking	was	as	
following;	low	=	less	than	33%	of	the	items	was	positively	answered,	medium	=	33–66%	and	
high	over	66%	of	the	questions	was	answered	positively	(see	Table	3.)		
Number	of	studies	included	in	the	review		
A	total	of	12,779	citations	were	obtained	from	the	database	searches.	After	the	initial	
reading	titles	and	abstracts	570	studies	were	identified	as	being	relevant	for	the	review.	Full	
papers	for	these	studies	were	obtained	for	further	reading.	A	total	of	83	papers,	
representing	76	unique	studies	were	retained	for	inclusion	into	the	review	(Fig.	1).		
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Fig	1	Identification	of	studies	for	review	
The	main	features	of	studies	included	in	the	review	have	been	presented	in	Table	3.		
General	study	characteristics		
Table	3	shows	that	the	availability	of	studies	to	review	increased	with	each	decade	with	the	
number	of	available	studies	to	review	in	the	last	decade	(2000–2010)	(n	=	39;	47%)	nearly	
double	those	available	in	the	nineties	(n	=	20;	24%)	and	nearly	eight	times	more	than	those	
available	in	the	eighties	(n	=	5;	6%).		
The	majority	of	the	studies	reviewed	were	conducted	in	Europe	(n	=	54/83;	65%)	with	the	
UK	and	Ireland	representing	the	largest	proportion	of	these	(n	=	38/83;	46%).	The	second	
largest	set	of	studies	originated	from	Australasia	(n	=	20/83;	24%)	while	North	America	
accounted	for	approximately	10%	(n	=	8)	of	the	studies	reviewed.		
In	the	majority	of	studies	the	use	of	theoretical	framework	was	not	mentioned	or	reason	for	
absence	stated	(n	=	67/83;	81%).	A	number	of	different	theories	featured	in	the	studies	
reviewed;	a	few	couple	of	studies	were	based	on	the	same	theoretical	underpinning.		
Features	of	consultations	for	NPMs		
Consistent	with	the	aims	of	the	study,	the	roles	of	other	staff	in	addition	to	pharmacists	
were	examined.	In	many	of	the	studies	it	was	difficult	to	distinguish	which	of	the	pharmacy	
staff	had	been	involved	in	supply	of	NPMs.	The	involvement	of	pharmacists	and	pharmacy	
staff	in	consultations	of	NPM	included	four	key	aspects	namely:	questioning	and	information	
gathering,	product	recommendation	and	sale,	provision	of	information	and	advice,	and	
referrals	(Fig.	2).	The	results	here	attempt	not	only	to	describe	these	activities	that	are	
undertaken	during	a	consultation	for	NPMs	but	also	describe	whether	these	activities	were	
carried	out	effectively.	
	
	
9	
Criterion	 Category	 No	of	studies	and	reference		
Year	 1980	-	1989	 5				(9,	10,11,12,	13)		
		 1990	-	1999	 20		(14,	15,	16,17,	18,19,	20,21,	22,23,24,25,26,27,28,	29,30,31,32,33)	
		 2000	-	2009	 38				(34,35,36,37,38,	39,40,41,42,43,	44,	45,	47,48,51,52,	54,	56,	57,	58,59,60,61		
62,63,64,	65,66,67,68,	69,70,71	,77,81)	
	
		 2010	-	2013	 20		(15,57,58,73,	74,	76,	77,	81,78,79,80,81,82	,83,84	,85,86,90,91)	
	
Countries	 Australasia	 		
		 Australia	 18		(12,	37,	38,	41,42,48,	50,52,53,55,62,80,82,86,87,89,90,91	
		 New	Zealand	 2	(54,70)	
		 North	America	 		
		 Canada	 3		(51,32,33)		
	
		 USA	 5		(14,	22,28,	56,60)	
		 Germany	 4		(34,39,76,79)	
		 Ireland		 	1	(	19)	
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		 UK	 37		(10,11,13,15,16,17,18,	20,21,25,26,27,28,29,31,35,43,5547,57,59,61,63,65.66,	
67,68,72,75,77,78,	81,83,84,88	
		 The	Nordic	countries	 		
		 Denmark	 1	(85)	
		 Finland	 3			(	23,	49,	58)	
		 Norway	 1	(44)	
		 Sweden	 6			(24,	26,	69,70,71,74)	
		 The	Netherlands	 1	(9)	
		 Transnational		(Australia,	Germany	and	UK)	 1{40)		
Data	collection	
methods	
Focus	groups	 3		(46,49,60)	
	
		 Interviews	 32		(	9,10,11,18,20,21,	25,35,41,42,46,48,51,52,56,57,62,67,69,70,73,,77,78,80,		
81,83,84,85,	87,88,91)	
		 Audio-recording	consultations	 4		(16,17,18,29)		
	
		 Observations	 17	(9,	16,17,19,20,21,	26,30,32,33,36,41,42,47,49.61,63,65)	
	
		 Mystery	shopper	 		
		 with	feedback)used	as	an	intervention	 11	(37,38,39,76,50,53,58.63,64,65,66,91)	
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		 used	to	report	back	on	aspects	of	consultation	 10	(14,22,28,34,74,12,44,54,59,86)	
	
	
		 Audit	type	recording	of	activities	related	to	consultations	for	NPMs	or	use	of	
community	pharmacies	
16	(13,15,24,31,43,45,	46,68,69,70,71,72,75,77,81,82,90)	
		 Health	diaries	and	other	records	made	by	patients	 5	(10,11,47,55,89)	
		 Surveys	 7	(40,	55,70,77,81,89,71)	
	
		 Critique	of	video-vignettes	 1	(23)	
General	study	
themes	
		 		
		 Observing	/	examining	aspects	of	consultations	or	use	of	NPMs	 51	(	9,12,13,14,16,17,18,19,20,21,22,23,24,29,30,31,32,33,34,36,37,38,39,41,42,47,	49.51,53,54,58,	
59,60,61,63,64,65,66,68,72,74,76,77,79,	81,82,86,90,91)	
	
		 Recording	'auditing'	aspects	of	consultations	 2	(43,45,68)	
	
		 Work	sampling	 3	(26,15,75)	
		 Exploring	experiences	and	perceptions	of	 		
		 Pharmacists	 8	(48,49,57,61	67,83,84,88)	
	
	
12	
		 Pharmacy	staff	(pharmacists	and	non-pharmacists)	 2	(78,	91)	
		 GPs	 1	(65)	
		 Customers	 18	(9,18,20,21,25,27,41,42,47,	52,56,60,62,73,80,85,87)	
		 Customers	as	'representatives'	 4	(10,11,77,81)	
	
		 Equipping	/	supporting	customers	to	manage	minor	ailments	 2		(55,89)	
	
		 Upskilling	pharmacy	teams	to	provide	better	customer	care	/	change	to	practice	
to	improve	customer	care	
4{35,	40,70,71)	
		 Increasing	access	to	care	 1	(46)	
Participants/those	
involved	
Pharmacists	 28	(12,14,	5,18,22,26,28,29,30,40,43,48,49,53,	57,58,59,	58,61,69,75,76,77,79,81,	
	83,84,86.)	
	
	
		 Pharmacy	staff	(pharmacists	and	non-pharmacists)	 35	(9,16,17,19,20,21,24,31,32,33,34,35,36,37,38,39,41,42,44,47,50,	54,63,64,65,66,68,70,71,	
72,74,78,89,90,91)	
	
	
		 GPs	 2		(40,57)	
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		 Customers	 26(	9,13,18,20,21,27,41,42,43,46,47,51,52,54,56,60,61,62,68,70,73,80,82,85,87,89)	
	
	
		 Customers	as	'representatives'	 5	(77,81,10,11,	58)	
	
Theoretical	
framework	
Agenda-led	outcome	based	analysis	(ALOBA)	 1	(66)	
		 Cognitive	psychology	perspective	 1	(23)	
	
		 Education	outreach	based	on	IDEALS	 2	(63,65)	
	
		 Grounded	theory	 2	(20,21)	
	
		 Human	error	theory	 2	(63,65)	
	
		 Motivational	interviewing	 2	(53,91)	
	
		 Pharmacy	practice	risk	management	framework	 1	(48)		
		 Self-management	theory	 1	(89)	
		 Self-regulation	of	illness	behaviour	 1{55)	
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		 Theory	of	planned	behaviour	 2	(56,	67)		
	
		 Transtheoretical	framework	of	change	 2	(43,68)		
	
Quality	Score	 HIGH	++	 53(14,15,16,17,18,20,22,24,34,35,	37,39,41,42,44,45,	48,49,50,51,52,54,55,56,	57,58,	
59,60,61,62,63,64,65,66,67,68,70,71,72,73,76,77,78,79,80,81,83,84,85,86,87,89,90,91)	
		 MEDIUM+	 23	(	9,10,11,13,19,21,23,25,26,27,29,31,32,36,40,43,53,69,	74,75,76,82,88)		
	
	
		 LOW	-	 6	(12,28,30,33,38,46)	
	
		 Not	possible	TO	SCORE	 1		(47)	
	
	 	 	
	 	 	
	 	 	
	 	 	
	 	 	
	 	 	
	 	 	
	 	 	
	 	 	
	 	 	
Table	3	Characteristics	of	studies	
	
	
15	
	
	
 
 
 
 
	
Fig.	2	Schematic	of	a	person's	visit	to	the	pharmacy	and	the	roles	undertaken	by	the	
pharmacy	team.	Questioning	and	information	gathering	from	customers		
 
 
A	number	of	studies	included	in	the	review	reported	on	pharmacy	staff	questioning	and	
gathering	information	from	people	during	a	consultation	for	an	NPM	before	a	differential	
diagnosis	could	be	pronounced	and	subsequent	action	in	response	to	this	diagnosis	
undertaken.		
Approaches	taken	by	the	different	studies	reviewed	to	capture	this	information	varied	
widely	and	included	reporting	on	number	of	questions	or	which	questions	were	asked	or	
proportion	of	consultations	where	questions	were	
asked12,14,29,34,39,50,54,59,66,74,76,77,86;	reporting	of	the	appropriateness	of	the	
questions	asked	or	questioning	style16,59;	reporting	on	the	appropriateness	of	patient	
assessment20,22,23,40,58,65;	reporting	on	change	in	use	of	questioning	behavior	following	
an	intervention53,66;	and	reporting	on	consumers'	experience	and	expectation	of	
questioning	by	pharmacy	staff.25,85		
Because	this	feature	of	the	consultation	was	measured	using	different	measures	it	is	not	
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possible	to	provide	a	single	overall	outcome	of	how	questioning	was	performed,	but	in	
general	terms	the	studies	indicated	that	adequate	questioning	and	information	gathering	
was	not	carried	out	fully	or	consistently	during	consultations.	Pharmacy	staff	were	seen	as	
lacking	the	necessary	questioning	skills,	listening	skills	and	knowledge	to	undertake	
adequate	information	collection65	and	advice	provision	as	a	reason	for	not	questioning	
customers	properly.	On	the	other	hand,	assuming	customers'	knowledge	of	products	as	a	
result	of	previous	purchase	was	also	reported	as	a	reason	why	questioning	was	not	done	
effectively.77	Criticism	was	directed	toward	pharmacy	staff	in	their	use	of	mnemonics;	this	
was	described	as	sometimes	being	‘wooden	or	unresponsive.’16		
Pharmacy	staff	performed	better	when	they	were	responding	to	symptoms	compared	to	
when	they	were	approached	by	a	patient	with	a	direct	product	request.	This	included	
attaining	higher	overall	scores	when	responding	to	symptoms	in	terms	of	questioning74;	
undertaking	the	process	of	questioning	more	effectively,54	and	achieving	higher	levels	of	
appropriate	patient	assessment	when	responding	to	symptoms.22	There	was	an	indication	
from	some	studies	reviewed	that	in	reality	pharmacy	staff	are	faced	with	more	product	
demands	from	customers	rather	than	being	presented	with	symptoms.20,72	It	was	
suggested	therefore	that	in	practice,	pharmacy	staff	are	in	fact	likely	to	be	dealing	with	
customers	who	know	what	they	want	and	may	account	for	the	reported	hostility	and	
negative	customer	response	directed	at	pharmacy	staff	when	attempting	to	question	
customers20,65	On	the	other	hand	the	negative	manner	in	which	customers	responded	to	
questioning	by	pharmacy	assistants	rose	suspicion	amongst	staff	that	a	customer	was	in	fact	
misusing	a	product.78		
Telephone	interviews	revealed	that	when	it	came	to	unsolicited	questioning,	there	was	
different	expectation	of	being	questioned,	awareness	of	why	questions	were	asked	or	the	
degree	to	which	the	person	was	responsible	to	volunteer	information	to	the	pharmacy	staff	
even	if	it	had	not	been	requested.25	Furthermore,	people	mentioned	the	challenges	
associated	with	attempting	to	answer	questions	on	behalf	of	another	person	for	whom	they	
were	purchasing	medicines.	Challenges	included	not	having	sufficient	information	about	the	
other	person	the	pharmacy	staff	were	enquiring	about	in	order	to	provide	comprehensive	
answers	to	questions	and	sharing	confidential	medical	problems	of	the	third	party	with	
pharmacy	staff.		
The	use	of	additional	support	aids	during	the	consultation	such	as	the	use	of	pharmacy	
decision	support	system	(PDSS)	showed	that	this	resulted	in	community	pharmacists	
covering	a	wider	range	of	mandatory	questions	to	confirm	appropriateness	of	self-
medication.76		
The	studies	also	revealed	that	there	was	scope	to	improve	the	pharmacy	staff's	questioning	
behavior	through	the	use	of	interventions.	A	study	that	used	mystery	shopper	with	
feedback	reported	an	improvement	in	the	use	of	open-ended	questions	from	a		
baseline	score	of	0.03%–39.5%	as	this	intervention	significantly	improved	this	aspect	in	the	
intervention	group	from	0.03%	to	68%.87		
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Through	the	process	of	questioning	and	information	gathering	pharmacy	staff	were	able	to	
identify	and	deal	with	drug	related	problems;	in	some	instances	drug	issues	were	missed	by	
pharmacy	staff.34	Example	of	drug	related	problems	picked	up	included	inappropriate	self-
medication,51,79	requested	product	inappropriate,72,79	intended	duration	of	drug	use	to	
high,79	wrong	dosage,79	unsure	of	indication	of	medication,69	or	therapy	failure.69	One	
study	reported	identifying	at	least	one	drug-related	problem	in	19.5%	of	product	requests	
and	in	12.5%	of	symptom	presentation	requests.79	This	same	study	showed	that	using	a	
person's	medical	history	when	checking	the	suitability	of	use	of	NPMs	resulted	in	issues	such	
as	wrong	dosage	and	drug–drug	interactions	to	be	picked	up	more	readily.79	In	some	
instances	patients	were	the	ones	who	picked	up	the	drug	related	problems	and	relayed	
these	to	the	pharmacy	staff36,69,70	to	deal	with.	A	study	that	audited	the	number	of	drug	
related	problems	identified	depending	on	whether	sales	of	NPMs	in	pharmacies	occurred	
over	the	counter	or	through	a	self-service	area	revealed	that	on	average	the	identification	of	
drug	related	problems	was	60%	higher	in	the	pharmacies	selling	NPMs	over	the	counter.69		
Some	pharmacists	were	commended	for	helping	people	to	seek	help	for	their	misuse	
through	questioning	the	frequent	users	of	codeine.87	Both	pharmacists78	and	patients87	
viewed	interactions	regarding	dealing	with	product	misuse	as	a	negative	experience.		
Product	recommendation	and	sale		
Product	recommendation	or	sale	of	an	NPM	following	response	to	symptoms	or	a	direct	
product	request	was	a	common	feature	of	NPM	consultations	studied	in	this	review.	As	the	
conditions	for	which	the	NPMs	were	recommended	and	sold	varied	widely,	so	did	the	
classes	of	medicines	supplied.	Product	recommendation	in	the	pharmacies	was	usually	for	
self-use,	however	obtaining	NPMs	for	another	person,	especially	children,	was	also	a	feature	
observed	in	the	studies	reviewed.		
According	to	one	study,	many	people	(57%)	considering	purchasing	a	medicine	for	a	first	
time	identified	pharmacy	staff	as	the	single	most	important	influence	in	helping	them	make	
this	decision.41	Advertisements	of	medicines	both	in	pharmacies	or	through	the	media	
accounted	for	about	6%	of	this	influence.		
The	use	of	evidence-based	medicine	on	the	part	of	the	pharmacist	for	choice	of	product	to	
recommended	was	not	widely	reported,	where	this	was	studied	it	appeared	that	the	use	of	
evidence	by	pharmacists	in	product	choice	was	a	secondary	consideration.	The	main	
concern	of	these	pharmacists	studied	was	satisfying	themselves	of	lack	of	potential	harm	to	
the	customer;	their	primary	concern	was	patient	safety.67,83,84	In	spite	of	this	concern	for	
safety,	studies	revealed	that	in	some	cases	consultation	included	selling	of	products	where	
drug	interactions	have	been	missed	or	not	discussed	with	the	customer,34	inappropriate	
product	recommendations12,14,22,39,59,66,74,76	and	in	some	cases	no	product	being	
recommended	altogether	was	evident.74	Moreover,	there	were	reports	from	pharmacy	
staff	that	they	would	partake	in	selling	of	inappropriate	or	unnecessary	products	because	of	
the	pressure	they	felt	from	some	people.83		
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There	was	a	higher	number	of	people	who	came	into	the	pharmacy	with	a	brand	of	
medicine	to	purchase	in	mind	compared	to	those	who	did	not.41,42		
Some	positive	involvement	of	pharmacy	staff	had	in	product	recommendation	included	
helping	people	to	find	the	medicine	on	the	shelf	or	in	offering	people	alternative	products	to	
what	they	had	in	mind	or	had	previously	tried.	People	who	had	walked	into	the	pharmacy	
with	a	particular	brand	in	mind	were	in	some	instances	successfully	offered	cheaper	
products.41	It	was	noted	however,	that	in	some	cases	where	the	brand	was	a	sure	
preference	a	cheaper	substitute	would	not	usually	be	accepted.81	Where	someone	
presented	with	a	drug-related	problem	one	option	for	pharmacy	staff	was	to	recommend	a	
different	product.	Some	people	viewed	their	experience	in	a	negative	light	if	they	were	
expected	to	be	responsible	for	making	the	decision	on	what	product	to	purchase,	for	these	
people	the	pharmacist	was	deemed	to	have	failed	them	in	terms	of	providing	them	with	
direction.61		
Recommending	an	alternative	product	was	a	common	intervention	undertaken	by	
pharmacy	staff	in	response	to	identification	of	a	drug	related	problem.69,70,72,79		
Pharmacy	staffs'	monitoring	and	surveillance	of	sales	was	a	key	way	in	which	potential	
abusers	of	medicines	were	identified.43,68,78	In	fact,	for	both	pharmacist	and	pharmacy	
staff	(but	mainly	staff)	the	frequency	of	purchase	was	central	for	defining	and	identifying	
suspected	OTC	misuse	or	abuse.78	For	pharmacy	staff	factors	such	as	frequency	(been	in	
two	or	three	times;	buying	the	same	thing);	product	knowledge	(know	exactly	where	a	
product	is	kept;	know	exact	product	size);	large	quantities	being	purchased/requested;	
manner	in	which	customers	respond	to	questions;	negative	reaction	or	aggression	to	a	
refused	or	referred	sale;	use	of	lies	and	deception	to	attain	a	product	(pretending	to	buy	for	
another	person);	use	of	others	to	purchase	medicines	for	them	raises	suspicion	to	the	fact	
that	there	may	be	likely	product	misuse.78	Pharmacists	taking	part	in	an	intervention	that	
involved	identifying	instances	of	potential	abuse	and	misuse	provided	a	list	of	features	they	
suggested	could	discriminate	between	the	two	behaviors.68	These	features	for	misuse	
include	willingness	to	converse	with	pharmacists	to	seek	information	and	were	amenable	to	
advice	given	or	refusal	of	product.	On	the	contrary,	abuse	was	likely	where	products	were	
purchased	more	frequently,	negative	reaction	to	a	refused	sale,	justification	for	purchase	of	
product,	those	who	visited	the	pharmacy	in	a	particular	pattern.68		
Pharmacy	staff	placed	emphasis	on	using	regulatory	guidelines	and	formal	pharmacy	
procedure	for	instance	referring	to	pack	size	or	indication	changes	for	products;	recording	
sales	of	medicines	of	potential	abuse	in	the	pharmacy;	use	of	technology	able	to	control	and	
monitor	sales	as	a	means	of	managing	suspected	abuse.78	Refusing	a	sale	was	one	way	
pharmacists	dealt	with	the	problem	of	drug	misuse	and	abuse.78		
An	educational	intervention	to	support	the	implementation	of	evidence	based	guidelines	in	
CP	setting	for	the	treatment	of	vulvovaginal	candidiasis	showed	that	there	was	no	
difference	found	between	groups	when	reporting	on	the	proportion	of	visits	resulting	in	an	
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appropriate	sale	or	non-sale	of	the	anti-fungal	product	as	per	guidelines.64	This	appropriate	
outcome	was	found	to	be	highly	significantly	positively	associated	with	the	total	information	
score	and	WWHAM	score.63		
A	study	that	evaluated	the	impact	of	pharmacy	staff	in	terms	on	clinical	interventions	
related	to	pharmacy	and	pharmacy	only	medicines	showed	that	these	interventions	averted	
emergency	medical	attention	or	serious	harm	and	could	be	classed	as	potentially	life-saving.	
As	a	result	of	these	interventions	urgent	GP	visits	were	shown	to	have	been	avoided	and	so	
were	admissions	to,	and	emergency	departments,	standard	wards	and	intensive	care.	
Additionally,	exacerbations	of	an	existing	condition	and	adverse	drug	effects	were	also	
avoided.90		
Providing	information	and	advice	to	customers		
Many	studies	reported	on	aspects	of	provision	of	advice	and	information	to	customers	
during	pharmacy	consultations.	Similar	to	questioning	and	information	gathering,	many	
different	aspects	provided	the	focus	to	determine	whether	pharmacy	staff	carried	out	this	
role	effectively.		
While	pharmacists	were	identified	as	the	predominant	source	of	information	for	NPMs.62	
There	was	a	large	number	of	instances	where	no	advice	and/or	information	provision	was	
recorded.	One	study	demonstrated	the	disparity	of	advice	giving	between	pharmacies	by	
noting	that	when	comparing	pharmacies,	in	only	five	pharmacies	(50%	of	pharmacies)	did	
the	percentage	of	people	who	received	advice	(72%)	was	shown	to	be	greater	than	
percentage	that	did	not	receive	advice.16		
In	some	situations	advice	and	information	was	provided	if	the	person	prompted	the	
member	of	staff.33,39	One	observation	study	noted	people's	patterns	of	behavior	in	that	
more	of	them	looked	at	the	product	on	the	shelf	before	asking	for	advice.	Other	studies	
reported	on	provision	of	unsolicited	advice	and	information77	An	interview	study	with	
people	purchasing	laxatives	showed	that	it	was	customary	for	customers	to	search	shelves	
and	self-select	products	rather	than	engage	with	a	pharmacy	staff	member;	a	behavior	that	
was	borne	from	being	unsatisfied	with	level	of	assistance	received	in	the	past.52		
Timing	of	when	customers	asked	for	advice	was	grouped	into	those	who	sought	advice	after	
they	spent	time	looking	at	the	product	where	the	other	group	of	consumers	proceeded	to	
seek	advice	before	looking	at	the	product.32Difference	in	advice	and	information	provision	
was	identified	in	consultations	that	were	rooted	in	responding	to	symptoms	versus	those	
that	arose	from	a	direct	product	request.	Counseling	was	more	likely	to	be	given	when	
someone	presented	their		
symptoms	or	medical	problems	compared	to	situations	where	a	product	was	requested	by	
brand	name	or	therapy	group.49		
Where	written	information	was	given	one	study	reported	that	two-thirds	of	people	did	not	
read	the	written	information,	those	who	read	were	mainly	interested	in	administration	and	
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side-effects.9	With	regards	to	the	level	of	advice	provided,	most	did	not	want	more	verbal	
advice	(92%)	whereas	only	8%	mentioned	they	would	have	wanted	more	verbal	advice.9	
One	study	reported	that	people	felt	the	need	for	different	levels	of	advice	depending	on	
whether	they	had	purchased	a	medicine	before,	with	more	advice	and	information	thought	
to	be	needed	when	a	medicine	was	new.77		
Some	medicine-related	problems	were	dealt	with	by	pharmacy	staff	through	providing	
advice	and	information.	This	included	provision	of	counseling	on	the	offending	medicine	and	
its	associated	problems69,70,79	through	provision	of	written	material,79	or	through	
provision	of	practical	assistance	with	for	instance	devices.69,79	Although	pharmacists	were	
reported	to	provide	information	on	the	maximum	dose	of	codeine,	frequent	users	of	
codeine	accused	some	pharmacists	for	their	lack	of	a	proactive	approach	in	providing	
information	on	the	risks	of	codeine	but	instead	responded	reactively	once	problems	with	
misuse	had	deeply	embedded.87	Pharmacists	engaged	on	activities	such	as	drawing	on	
evidence	based	medicine,	their	clinical	knowledge	and	expertise	which	included	advising	
customers	when	it	came	to	deal	with	the	subject	of	medicine	abuse	and	misuse.78		
A	pilot55	that	examined	the	impact	of	goal	setting	against	provision	of	standard	care	for	the	
management	of	intermittent	allergic	rhinitis	showed	that	goal	setting	with	health	care	
professionals	of	the	pharmacy	team	showed	a	significant	reduction	in	symptom	severity	
measured	over	the	period	of	the	study,	with	the	patients	in	the	health	care	professional	
group	presenting	with	significantly	lower	mean	perceived	symptom	severity	scores	
compared	to	the	standard	care	group.	A	full	intervention	to	assess	this	intervention89	
revealed	that	there	was	a	significant	improvement	in	all	outcome	measures	over	time	within	
each	of	the	groups	(P	<	0.005),	but	no	significant	difference	between	control	and	
intervention	group	over	time.	However	allergic	rhinitis	self-efficacy,	symptom	severity,	and	
quality	of	life	improved	significantly	in	patients	assisted	by	pharmacy	staff.		
Another	intervention	study	showed	that	advice	given	from	a	pharmacist	lead	to	greater	
symptom	relief	by	those	people	who	reported	following	the	advice.71	Further	investigation	
to	review	those	whose	compliance	with	advice	was	classified	as	appropriate	by	the	
independent	assessors,	and	who	had	claimed	to	have	been	completely	compliant	with	
advice,	a	higher	number	from	this	group	experienced	great	relief	of	symptoms	than	those	
who	only	partially	followed	and	reported	the	same	level	of	improvement	(P	<	0.0001).71		
An	interview	study80	revealed	that	some	people	did	in	fact	leave	the	community	pharmacy	
with	unanswered	health	related	questions,	some	regarding	NPMs.	It	was	postulated	that	
adverse	events	that	may	result	because	of	this	may	include	non-	adherence,	suboptimal	
treatment	and	adverse	events	(for	all	the	unanswered	health	related	queries	not	just	the	
NPM	ones).	Past	unanswered	health-related	questions	served	to	highlight	that	the	
implications	of	having	unanswered	questions	related	to	NPMs	included	the	pharmacy	losing	
their	custom,	anxiety	over	the	use	of	medication,	a	delay	in	receiving	effective	treatment.		
The	age	of	the	patient	was	mentioned	as	a	factor	that	had	an	impact	on	provision	of	advice	
during	consultations	for	NPMs.	Younger	people	(aged	20–44	years	old)	were	significantly	
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more	likely	to	receive	advice	when	busying	medicines	than	people	aged	over	65	years.19	It	
was	also	reported	that	providing	advice	when	counseling	older	people	at	times	provided	
challenging	as	sometimes	older	people	were	not	clear	on	what	their	needs	were	and	at	
times	were	not	able	to	clearly	communicate	their	symptoms.49	It	was	also	mentioned	that	
people	from	different	cultures	at	times	had	problems	communicating	their	symptoms	which	
too	made	provision	of	advice	a	challenge.49		
An	interesting	aspect	reported	in	one	of	the	studies	was	the	amount	and	type	of	
information	and	advice	that	was	recalled.18	This	UK	study	showed	that	of	the	mean	13.74	
items	of	information	offered	to	someone	by	the	pharmacist	during	a	consultation,	only	a	
mean	of	3.26	(23.7%)	was	actually	recalled.	It	was	shown	that	procedural	advice	(36.9%)	
was	more	likely	to	be	recalled	than	non-procedural	advice	(17.5%)	(P	<	0.001)	in	this	study.	
Furthermore,	the	study	revealed	that	it	was	in	fact	information	that	was	repeated	more	
frequently	that	was	subsequently	recalled.		
Referrals		
Although	referrals	could	arguably	be	seen	as	an	extension	of	advice	provision,	the	
separation	here	is	in	recognition	that	within	consultations	for	NPMs	a	number	of	different	
types	or	referrals	took	place,	namely	referral	of	a	patient	from	pharmacy	staff	to	a	
pharmacist	within	the	community	pharmacy	setting,16,17,48,72,78	referral	of	patients	from	
pharmacy	staff	to	other	health	care	professionals	(usually	
GPs),10,18,21,24,28,31,37,39,4549,53,54,59,67,69–72,78,79	referral	from	other	health	care	
services	to	community	pharmacy	and	self-referral	to	GPs	by	people	via	the	community	
pharmacy	route.10,21,47		
In	cases	where	pharmacy	staff	suspected	that	they	were	dealing	with	misuse	cases	they	
would	refer	the	person	to	the	pharmacists.78	Occasional	signposting	and	involving	the	
people's	GP	was	a	strategy	used	by	pharmacists	in	dealing	with	medicine	misuse	and	
abuse.78		
Referring	people	to	other	health	care	professionals,	mainly	GPs	was	another	way	that	
community	pharmacy	staff	dealt	with	other	drug	related	problems	identified	during	
consultations	for	NPMs.69,72,79	One	study	did,	however,	illustrated	that	people	did	
erroneously	recall	being	referred	to	their	GP	by	the	pharmacist	when	in	fact	this	was	not	the	
case.18		
Although	pharmacists	had	referred	people	in	response	to	refusing	a	supply	there	was	
evidence	from	the	interviews	that	these	too	were	not	that	straight	forward	due	to	lack	of	
information	about	the	person	(and	therefore	not	being	able	to	get	in	touch	with	their	
doctor),	not	having	in-depth	knowledge	of	services	that	are	available	to	support	those	
abusing	medicines	and	using	a	method	of	cascading	information	of	someone	suspected	of	
abuse	although	used	by	some	was	not	always	practical	due	to	the	time	and	number	
logistics.78		
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A	number	of	studies	mentioned	that	some	people	undertook	a	visit	to	the	community	
pharmacy	as	a	‘stepping-stone’;	this	provided	a	legitimate	path	for	them	to	then	visit	the	
GP,	at	times	as	a	result	of	a	referral	from	community	pharmacy.10,11,21,47	There	were	
some	people,	however,	who	did	not	have	trust	in	NPMs,	and	for	these	customers	self-
referral	to	GP	was	the	chosen	option	to	deal	with	a	medical	condition.47		
At	times	referrals	were	deemed	to	be	inappropriate,21	with	the	‘play	safe’	attitude	of	
pharmacists	in	situations	of	doubt	and	uncertainty	accounting	for	some	of	these	
unnecessary	referrals.	With	regards	to	appropriateness	of	referrals	it	was	identified	that	
there	were	instances	when	community	pharmacy	staff	should	have	referred	someone	to	the	
GP	and	failed	to	do	so.39	In	addition	to	this,	the	reasons	why	referrals	did	not	make	it	to	
their	GP	is	because	people	did	not	always	follow	advice	from	the	pharmacy,	even	in	
situations	where	in	follow-up	consultations	people	had	promised	to	visit	their	GP	as	per	
referral.49,70	Sometimes	advice	from	pharmacist	to	visit	GP	was	not	heeded	as	the	
customer	felt	that	their	symptoms	did	not	warrant	such	a	visit.18	Consequently,	there	was	
concern	among	community	pharmacy	staff	that	having	consultations	and	at	times	the	
provision	of	an	NPM	in	a	delayed	referral	in	fact	may	serve	as	a	barrier	to	going	to	the	GP	
and	had	a	potential	of	masking	a	serious	medical	problem.67	In	fact,	another	study	reported	
that	57%	of	people	questioned	would	have	taken	their	medical	problem	to	the	GP	if	a	
pharmacy	service	supplying	NPMs	was	not	available.	It	was	recognized	however	that	referral	
was	not	always	easy,49	and	ultimately	the	person	has	to	be	willing	to	go	to	the	GP.70	
Interventions	to	improve	referrals	showed	that	at	times	these	did	not	have	a	significant	
impact37	and	at	times	interventions	did	increase	the	number	of	referrals.70		
Factors	affecting	consultations	of	NPMs		
Pharmacists	versus	non-pharmacist	involvement		
Reviewing	studies	that	measured	the	involvement	of	pharmacists	and	non-pharmacist	staff	
in	consultations	for	NPMs	showed	that	non-pharmacist	staff	dealt	with	more	of	the	
consultations	than	did	pharmacists.16,17,31,63	Pharmacists	were	usually	involved	in	these	
consultations	by	invitation	from	pharmacy	staff	as	cases	were	referred	to	the	pharmacist	for	
their	input.	Pharmacists	interviewed	about	their	confidence	in	delegating	the	supply	of	
NPMs	to	pharmacy	staff	all	pronounced	their	confidence	in	these	staff	for	the	role	with	the	
knowledge	that	if	unsure	the	staff	would	approach	the	pharmacists	for	clarification	and	
advice.48	Evidence	of	this	in	practice	can	been	seen	where	medicine	counter	assistants	
observed	showed	that	referrals	to	pharmacists	from	pharmacy	staff	was	largely	for	
gastrointestinal	symptoms	when	compared	with	respiratory	or	ear,	nose	and	throat	
symptoms,	the	pharmacy	staff	felt	more	knowledgeable	in	dealing	with	the	latter	two	and	
they	felt	these	conditions	were	less	serious	than	gastrointestinal;	symptoms.16,17		
Studies	that	compared	outcomes	of	various	aspects	of	consultations	for	NPMs	by	
considering	which	member	of	the	pharmacy	team	was	involved	in	the	consultation	revealed	
that	pharmacists	tended	to	perform	better	than	pharmacy	staff.16,19,34,37,38,64	Although	
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observational	data	showed	that	the	involvement	of	pharmacists	in	consultations	for	NPMs	
were	generally	opportunistic	and	unplanned	in	nature,	pharmacists	provided	advice	in	
almost	twice	the	number	of	consultations	when	compared	with	pharmacy	staff.16	
Pharmacists	performed	significantly	better	in	questioning	people	and	eliciting	information	
from	them,63	and	pharmacists	conducted	more	guideline-compliant	consultations.63–65	
Another	observation	study	showed	that	significantly	more	consultations	for	medicines	sales	
that	involved	pharmacists	were	accompanied	by	counseling	when	compared	with	
consultations	carried	out	by	pharmacy	staff.19	Pharmacists	also	achieved	higher	
consultations	scores	when	involved	in	responding	to	symptoms	when	compared	with	
pharmacy	staff.37	Pharmacists	were	found	to	have	a	higher	chance	of	identifying	and	
commenting	on	interactions.34		
Where	consultations	involved	both	the	pharmacist	and	pharmacy	staff,	observation	studies	
revealed	that	these	consultations	were	performed	much	better	than	with	any	pharmacy	
team	member	alone.16,64	In	one	study,	97%	of	consultations	that	involved	both	pharmacist	
and	pharmacy	staff	saw	customers	receiving	advice.16	Teaming	of	pharmacists	and	
pharmacy	staff	resulted	in	a	higher	proportion	of	appropriate	sales	or	compliant	
consultations	compared	to	either	group	of	staff	carrying	out	these	consultations	on	their	
own.63–65	
Responding	to	symptoms	versus	direct	product	requests		
Although	studies	reviewed	suggested	that	consultations	for	product	requests	outnumbered	
those	that	involved	symptom	presentation65,84	it	was	in	fact	consultations	that	involved	
symptom	presentation	that	were	conducted	to	a	higher	standard	when	compared	with	
those	where	someone	asked	directly	for	a	product.37,38,65,84,91	Mystery	shopper	with	
feedback	intervention	studies	showed	that	although	overall	consultation	scores	improved	
following	the	intervention,	responding	to	symptom	consultations	scored	higher	than	direct	
product	requests.37,38	However,	in	terms	of	improvement	from	baseline,	the	consultations	
for	direct	products	requests	improved	more	than	consultations	for	responding	to	
symptoms.38	Compliance	with	guideline	recommendation	was	more	evident	when	dealing	
with	scenarios	involving	symptom	presentation	compared	to	product	requests.65	
Pharmacists	reported	that	they	felt	they	had	more	control	and	flexibility	when	coming	to	
making	decisions	of	product	to	supply	when	people	presented	symptoms	rather	than	asking	
for	a	specific	product.84		
A	mystery	shopper	with	feedback	intervention	study39	indicated	that	communication	within	
consultations	involved	with	responding	to	symptoms	was	significantly	much	better	than	in	
direct	product	request	consultations	in	terms	of	length	of	sentence,	use	of	open-ended	
questions,	overall	impression	of	counseling	service.		
Brand	in	mind	or	no	brand	in	mind		
A	vast	majority	of	people	visited	a	pharmacy	to	purchase	a	medicine	when	they	already	had	
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a	particular	brand	in	mind.41,42	A	majority	of	these	people	proceeded	to	buy	the	medicine	
they	had	in	mind.	Approximately	one-fifth	of	these	people	bought	the	medicine	without	a	
consultation.42	The	majority	of	these	who	had	brand	in	mind	asked	the	pharmacy	staff	for	
the	medicine	and	approximately	a	tenth	self-selected	the	product	themselves	without	first	
consulting	pharmacy	staff.41	On	the	contrary,	when	people	made	a	visit	to	the	pharmacy	
without	a	particular	brand	in	mind,	most	of	the	medicine	sales	that	followed	resulted	from	
the	person	making	some	form	of	request,	although	a	small	percentage	of	these	people	
made	an	unguided	selection	from	the	product	shelves.41,42		
Time	available	or	allocated	to	consultations	for	NPMs		
Interviews	conducted	with	pharmacists	following	a	health	promotion	campaign	carried	out	
in	the	pharmacy	revealed	that	pharmacists	felt	that	the	pharmacy	staff	team	did	not	have	
enough	time	to	speak	with	people.35	In	sales	of	medicines	governed	by	standards	for	the	
provision	of	Pharmacist	Only	and	Pharmacy	Medicines	in	community	pharmacy	(S2/S3	
standards),	sales	for	S3s	(where	pharmacists	had	to	be	involved)	pharmacists	reported	not	
having	enough	time	to	attend	to	every	request	for	an	S3	and	at	times	limited	their	
involvement	to	verifying	standardized	tick	box	forms	completed	by	support	staff	to	confirm	
the	therapeutic	appropriateness	of	treatment	being	proposed	to	be	supplied	to	the	
customer,	therefore	there	input	in	supply	of	S3	was	at	times	very	limited.48		
An	assessment	of	how	pharmacists	used	their	time	in	community	pharmacy	showed	less	
time	was	devoted	to	their	involvement	with	consultations	for	NPMs	compared	to	the	time	
devoted	to	completing	mechanical	tasks,	not	requiring	the	expertise	of	the	pharmacist,	such	
as	product	assembly	and	labeling.15,75	The	activity	that	pharmacists	gave	their	least	
amount	of	time	to	was	staff	training.15,75		
Studies	that	involved	work	sampling	showed	that	even	when	the	pharmacy	was	facing	a	
busy	period,	the	time	spent	providing	advice	on	NPMs	remained	steady.26	However,	the	
volume	of	prescriptions	dispensed	in	a	pharmacy	impacted	how	much	time	pharmacists	
engaged	in	counseling	for	the	supply	of	NPMs	or	responding	to	symptoms.	Significantly	less	
time	was	spent	on	these	activities	in	pharmacies	with	higher	volumes	of	prescriptions	
dispensed.15,75	An	intervention	study	using	mystery	shoppers	resulted	in	people	receiving	
significantly	longer	consultations	with	counseling	times	increasing	to	5.1	min	from	the	
original	3.6	min	before	the	mystery	shopper	visit.76	Interviews	conducted	following	a	
service	evaluation	reported	that	pharmacy	staff	believed	that	people	would	benefit	if	there	
was	more	interaction	with	the	pharmacy	staff	and	if	more	time	is	spent	on	the	
consultation.57		
Attributes	of	community	pharmacy	where	NPMs	are	supplied		
Community	pharmacists	were	viewed	by	some	people	as	medicine	experts47	and	they	felt	
that	pharmacy	staff	had	the	expertise	required	to	deal	with	their	medical	complaints.85	
Involving	pharmacy	staff	in	an	intervention	that	involved	identifying	product	misuse	led	to	
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raising	awareness	amongst	them	and	made	them	realize	their	vital	role	they	had	in	
supporting	patients	to	use	medicine	safely.68		
Some	customers	felt	that	community	pharmacy	served	the	same	function	as	the	GP.11	
People	reported	that	the	approachability	of	pharmacy	staff	and	their	ability	and	willingness	
to	spend	more	time	dealing	with	them	was	a	positive	of	visiting	the	community	
pharmacy.47		
People	used	the	community	pharmacy	instead	of	visiting	the	GP	as	a	way	to	reduce	GP	
workload	or	prevent	unnecessary	workload	on	GPs.21,46,47,57,88	At	times	when	people	
were	not	satisfied	with	the	outcome	of	their	GP	visit	the	community	pharmacy	was	seen	as	
the	place	to	go	as	an	alternative	to	the	GP.10,11,47	One	pharmacy	design	was	intentional	in	
displaying	P	medicines	as	dummy	packs	where	people	could	self-select	them	as	a	way	of	
engaging	people	more	in	the	decision-making	of	purchase	of	NPMs	and	was	reported	to	
have	improved	access	and	engagement.61		
Using	community	pharmacy	was	seen	as	a	way	to	improve	access	to	care,	it	was	said	to	
improve	peoples'	choices	(e.g.	compared	to	what	products	the	GP	could	offer),27,57	and	it	
was	seen	as	a	way	of	channeling	people	to	the	right	care	setting.47		
The	community	pharmacy	setting	was	used	as	it	was	reported	to	be	
convenient21,27,47,57,67,85,88	and	time-saving.27,67	People	reported	using	the	
community	pharmacy	out	of	habit.85Community	pharmacies	were	used	due	to	ease	of	
access,	which	for	some	this	specifically	meant	not	needing	to	make	an	appointment21,27,47	
or	not	having	to	wait.27	An	additional	advantage	reported	was	the	benefit	of	being	able	to	
have	consultations	and	medical	issues	attended	to	‘by	proxy.’21,47,72		
In	some	cases	community	pharmacy	was	seen	as	the	affordable	option	for	people.21,27,57	
Buying	NPMs	worked	out	as	a	cheaper	alternative	in	some	instances.27		
Overall,	pharmacists	and	pharmacy	staff	were	commended	for	their	good	communication	
skills14,39	and	interpersonal	skills.22	At	times	standard	of	communication	was	concluded	to	
be	excellent	by	those	who	mystery	shopped	pharmacies.12	Some	mystery	shoppers	
described	the	pharmacist's	style	of	communication	as	empathetic.86	Pharmacists	reported	
adapting	their	communication	style	and	interacted	with	people	in	response	to	nonverbal	
signs	(reading	expressions,	appearance	of	the	eyes	and	specific	motions)	given	by	people	
during	consultations.49	Pharmacists	realized	their	responsibility	for	lifelong	learning	
involved	with	pharmacy	even	with	regards	to	an	area	such	as	communication,	they	
identified	that	they	were	responsible	to	maintain	their	training	and	keep	up	to	date.61	
Being	able	to	speak	and	share	the	same	language	as	people	form	a	minority	ethnic	
background	was	viewed	as	an	important	role	of	pharmacy	staff	from	the	same	minority	
ethnic	background.	Having	a	shared	language	facilitated	in	communicating	details	of	a	folic	
acid	health	promotion	in	the	pharmacy	with	people	with	whom	they	shared	the	same	
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ethnicity	and	language.35		
On	the	contrary	to	the	positive	aspects	of	community	pharmacy	highlighted	above,	negative	
features	that	were	reported,	including	some	people	who	felt	that	it	was	embarrassing	to	
have	to	discuss	their	ailments	at	the	pharmacy,41,67	and	a	lack	of	privacy.41,60,67	The	
overall	layout	of	the	community	pharmacy	setting	was	also	seen	as	a	barrier	to	
communication.60	People	reported	that	communicating	with	pharmacy	staff	was	not	
always	that	easy,	as	pharmacists	at	times	appeared	to	be	busy,60,85	and	perhaps	more	busy	
than	they	really	were	as	a	strategy	to	avoid	communicating	with	people60	and	hence	were	
seen	as	unapproachable.		
Some	people	did	not	believe	NPMs	to	be	potent	enough	and	preferred	to	obtain	more	
potent	ones	from	their	GP.27	In	fact,	an	interview	study	of	the	use	of	evidence	based	
medicine	by	pharmacists	in	the	area	of	NPMs	revealed	that	discussing	the	lack	of	evidence	
of	the	effectiveness	of	NPMs	was	not	easy	for	pharmacists	and	reflected	on	the	ethics	of	
selling	NPMs	were	evidence	of	effectiveness	has	not	been	confirmed.83	They	explained	that	
reasons	that	made	it	uncomfortable	to	discuss	the	lack	of	evidence	of	the	effectiveness	
included	dealing	with	product	popularity	and	not	wanting	to	destroy	peoples'	confidence	in	
a	particular	product.	Furthermore,	an	additional	challenge	put	forth	was	the	possible	
conflict	of	interest	in	using	evidence	based	practice	as	the	community	pharmacy	was	in	fact	
a	retail	business.83		
There	appeared	to	be	a	lack	of	awareness	and	confusion	about	the	role	of	the	community	
pharmacy,	and	it	was	the	view	of	some	people	that	it	was	not	in	the	pharmacist's	area	of	
expertise	to	be	involving	themselves	with	diagnosis	illnesses47	or	medicines	
management60;	rather,	their	role	was	mainly	that	of	filling	prescriptions60	and	pharmacist	
were	not	to	interfere	where	medicines	are	recommended	by	the	GP60,85;	the	GPs	were	the	
ones	who	possessed	the	knowledge.85		
Discussion	
Discussion	of	key	findings		
Numbers	of	studies	to	review	increase	year	on	year	and	the	trend	over	the	last	5	years	
indicates	that	the	number	of	studies	relevant	to	the	supply	of	NPMs	in	community	
pharmacies	continues	to	rise.	The	majority	of	the	studies	were	conducted	in	the	UK	and	
Ireland	and	the	second	largest	group	of	studies	covered	the	Australia	and	New	Zealand	
which	have	a	similar	community	pharmacy	context	to	the	UK.	Scoping	studies	further	afield	
from	other	European	countries	and	North	America	helped	shed	some	insight	into	the	
realities	to	be	considered	if	NPMs	are	made	available	for	self-selection.	Studies	included	in	
the	review	were	often	small	and	of	low	quality	with	small	sample	sizes.	If	interventions	and	
practice	changes	are	derived	from	methodologically	weak	interventions	they	may	be	
implemented	or	rejected	in	error.	It	may	seem	surprising	that	more	large	studies	about	
pharmacist	supply	of	NPMs	have	not	been	conducted.	However,	pharmacy	chains	have	not	
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had	a	history	of	conducting	research,	and	research	training	for	community	pharmacists	and	
research	networks	did	not	exist	until	fairly	recently.	The	recent	growth	of	research	networks	
and	the	increasing	amount	of	research	being	conducted	by	pharmacy	chains	in	the	UK	and	
beyond	is	encouraging	and	may	led	to	an	increase	in	larger	higher	quality	national	and	
international	studies	which	would	have	been	difficult	to	conduct	before.		
Is	the	pharmacist	important	in	the	supply	of	NPMs?		
The	primary	aim	of	this	systematic	review	was	to	identify	and	summarize	the	available	
evidence	of	the	role	pharmacists	play	in	maintaining	and	guaranteeing	patient	safety	and	
improving	the	quality	of	consultations	for	supply	of	P	medicines,	and	to	establish	whether	or	
not	the	intervention	of	a	pharmacist	is	important	in	the	sale	of	P	medicines	in	community	
pharmacies.	Although	some	studies	did	exclusively	include	pharmacists5,12,14,18,22,26,28–
30,40,43,48,49,53,57–59,61,69,75–77,79,81,83,84,86	as	participants	in	studies	undertaken	
and	in	some	settings	pharmacists	did	not	have	support	staff,	it	was	evident	from	most	of	the	
studies	reviewed	that	non-pharmacist	staff	featured	largely	in	consultations	for	NPMs	and	
play	a	significant	role	in	the	supply	of	NPMs.16,17,31,63	It	is	interesting	that	pharmacists	
tended	to	perform	better	than	pharmacy	staff16,19,34,37,38,64	and	provide	advice	in	
almost	twice	as	many	consultations16	suggesting	that	further	training	and	better	use	of	
each	of	the	pharmacy	team's	skills	is	needed.	Perhaps	pharmacists	need	to	spend	more	time	
responding	to	customers'	symptoms	and	supplying	NPMs.	These	findings	clearly	indicate	the	
value	of	having	pharmacists	involved	in	supply	of	NPMs.		
Pharmacists	and	pharmacy	staff	were	commended	for	good	communication	skills12,14,39	
and	interpersonal	skills.22,86	However,	there	was	evidence	for	need	to	improve	all	aspects	
of	consultations	and	a	need	to	be	consistent	throughout	consultations,	as	all	aspects	play	a	
unique	role	in	enabling	appropriate	use	of	NPMs.	Information-gathering	by	pharmacists	and	
pharmacy	staff	through	questioning	people	is	not	always	carried	out	comprehensively,16,65	
with	factors	such	as	the	pharmacy	environment,41,60,67	lack	of		
elsevier_RSAP_717		
time,	lack	of	understanding	of	protocols	and	poor	communication	skills	being	mentioned	as	
contributors.	There	is	scope	to	improve	the	pharmacy	staff's	questioning	behavior	through	
the	use	of	interventions	such	as	mystery	shopper	with	feedback.87	Such	methods	could	be	
more	widely	used	to	improve	performance.	The	development	of	communication	and	
consultation	skills	should	be	prioritized	so	that	pharmacists	can	understand	and	engage	with	
the	patient's	own	discourse.	So	for	example,	a	patient	may	have	a	different	view	of	risk	from	
the	pharmacist	so	the	pharmacist	needs	to	help	the	patient	understand	the	risk	in	such	a	
way	the	patient	understands	how	to	take	the	medicines	and	is	not	put	off	doing	so.	Also	
training	programs	as	presented	in	the	papers,87	should	not	be	seen	as	one	off	events	but	an	
on	going	quality	improvement	process.		
Having	to	extract	information	from	unwilling	people	or	people	who	are	not	privy	to	the	
information	such	as	visits	to	the	pharmacy	made	by	proxy21,47,72	has	also	been	highlighted	
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as	a	barrier	to	information	gathering.	Notwithstanding	this,	the	fact	that	effective	
information	gathering	is	a	prerequisite	to	an	effective	consultation	process	outcome	
including;	provision	of	NPM,	refusal	to	provide	NPM	or	referral,	means	that	ways	to	
overcome	these	barriers	are	necessitated.	Ways	to	improve	the	pharmacy	environment	for	
example,	busyness,60,85	staff	levels,	competing	demands,	enhancing	pharmacy	staff	skills	
and	knowledge,	and	means	of	engaging	people	by	explaining	the	importance	of	gathering	
correct	information	and	explaining	why	information	is	being	asked,	may	also	prove	to	be	
helpful.60,85	If	more	NPMs	move	to	self-selection,	more	onus	is	likely	to	be	placed	on	
people	to	initiate	the	first	contact	with	pharmacy	staff.	If	people	select	an	inappropriate	
treatment,	for	some	the	result	may	be	negative	health	outcomes	and	could	lead	to	
prolongation	of	ailment,	deterioration	of	condition	and	suffering	unwanted	medicine	
effects.		
Although	staff	were	able	to	identify	and	deal	with	drug	related	problems51,69,72,79;	in	
some	instances	drug	issues	were	missed	by	pharmacy	staff.34	One	study	showed	that	drug-
related	problems	were	60%	higher	in	the	pharmacies	selling	NPMs	over	the	counter	than	if	
just	sold	via	self	selection.69	This	indicates	the	value	of	having	pharmacist	and	pharmacy	
staff	involvement	in	supply	rather	than	just	self	selection.		
Pharmacists	have	a	multifaceted	role	in	supply	of	P	medicines.	People	have	varying	
expectations	along	the	spectrum	of	expecting	questions,	advice	and	information	from	
pharmacists	and	their	staff	to	expecting	to	be	able	to	select	a	product,	purchase	it	and	leave	
without	being	asked	or	asking	any	questions.	As	Banks92	and	Stevenson61	have	discussed,	
all	of	this	takes	place	in	an	environment	that	is	rooted	in	both	health	and	commerce.	There	
is	an	interesting	balance	to	strike	between	treating	people	as	patients	or	customers	who	
know	what	they	wish	to	purchase	and	enabling	them	to	experience	health	care	and	be	
empowered	for	self	care.	There	is	a	lack	of	health	literacy	around	pharmacy	medicines,	and	
if	medicines	were	only	available	for	self-selection	or	on	prescription,	people	would	need	to	
be	much	more	educated	than	at	present	about	the	need	to	seek	advice,	particularly	if	they	
have	existing	long	term	conditions	for	which	they	are	taking	other	medicines.	Medicines	are	
not	like	any	other	commercial	product.	The	need	to	refer	people	in	an	appropriate	and	
timely	manner	to	a	more	suitable	health	care	such	as	the	GP	strengthens	the	case	for	
needing	meaningful	interactions	to	happen	between	customers	and	pharmacy	staff	for	
treating	minor	ailments	with	NPMs.		
Some	products	recommended	in	community	pharmacy	were	deemed	to	be	
inappropriate.51,69,72,79	This	review	identified	community	pharmacy	as	both	a	main	
source	of	products	that	are	misused	but	also	a	setting	that	provided	a	unique	position	to	
identify	misuse.78,87	The	identification	of	misuse	depends	on	knowing/seeing/being	
familiar	with	customers,	which	in	turn	was	made	possible	where	a	pharmacy	had	a	stable	
workforce	especially	of	frontline	staff.	This	makes	adequate	and	regular	staffing	of	
community	pharmacies	an	item	of	importance	for	patient	safety.	Because	noticing	the	
repeat	buying	of	the	same	product	can	help	identify	misuse	questions	should	be	asked	of	
pharmacy	settings,	such	as	some	supermarkets,	which	currently	display	medicines	at	
distances	away	from	the	actual	pharmacy.	Inconsistencies	in	process	outcome	for	customers	
when	they	visit	different	pharmacies	may	be	particularly	unhelpful	where	medicines	are	
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suspected	to	be	being	abused.	Therefore,	pharmacy	staff	should	be	consistent	in	the	criteria	
they	use	to	refuse	a	sale	for	an	OTC	that	is	suspected	as	being	misused/abused,	patients	
should	be	receiving	the	same	message	irrespective	of	which	pharmacy	they	visit	and	there	
should	not	be	a	tier	of	‘easy’	and	hard	pharmacies	or	staff	for	which	inappropriate	supplies	
of	medicines	are	made.	Adherence	to	protocols	and	guidelines	may	be	a	useful	aid	to	
achieve	this	consistency.	If	interaction	with	customers	is	removed	by	self-selection	it	can	
make	it	harder	to	identify	misuse	and	provide	support	and	guidance	to	customers.	In	the	
interest	of	patient	safety	extra	restrictions	(even	if	by	proximity)	should	be	considered	for	
medicines	which	are	likely	to	be	misused	if	a	move	to	self-selection	is	recommended.		
Provision	of	information		
While	pharmacists	were	identified	as	the	predominant	source	of	information	for	NPMs.62	
There	was	a	large	number	of	instances	where	no	advice	and/or	information	provision	was	
recorded.16	Provision	of	information	and	advice	is	a	crucial	element	of	consultations	for	
NPMs	which	in	light	of	protocols	of	sales	of	NPMs	would	be	deemed	unsatisfactory.	On	the	
other	hand,	the	review	showed	that	when	information	and	advice	was	imparted	customers	
did	not	retain	much	of	it	anyway	which	provides	a	challenging	paradox.	Where	written	
information	was	given,	one	study	reported	that	two-thirds	of	people	did	not	read	it.9	This	
emphasizes	the	importance	for	provision	of	verbal	information	at	the	time	of	supply.	Of	
note	was	the	fact	that	people	did	appear	to	recall	advice	that	was	repeated	and	that	
constituted	a	procedural	piece	of	advice/instruction.18	Intervention	studies	have	shown	
that	pharmacy	staff	advice71	and	goal	setting55,89	lead	to	greater	symptom	relief.		
In	reality	this	may	mean	that	pharmacy	staff	and	protocol	developers	need	to	acknowledge	
that	overloading	people	with	information	for	the	sake	of	adhering	to	a	protocol	is	not	going	
to	be	useful,	but	consideration	may	be	given	to	develop	protocols	and	consultation	styles	
that	include	intentional	repetition	of	key	information	to	communicate.	Ascertaining	what	
existing	knowledge	someone	holds	about	an	NPM	may	help	tailor	the	conversation	to	focus	
on	‘new’	areas.	As	it	is	not	possible	to	equip	people	with	all	the	necessary	product	
information	and	advice	in	one	consultation,	verbal	information	supplemented	with	either	
written	information	or	highlighting	reputable	sources	of	information	found	on	the	internet	
may	prove	useful.	Making	opportunities	to	speak	to	people	who	make	repeated	visits	to	the	
pharmacy	provides	an	avenue	to	build	their	product	knowledge,	whereas	this	review	
implied	that	for	these	people's	knowledge	is	sometimes	assumed	due	to	frequency	of	
purchasing	a	product,	which	in	fact	should	perhaps	alert	pharmacy	staff	of	further	
intervention	being	warranted.	In	addition	to	this,	people	may	need	to	be	alerted	to	changes	
in	product	advice,	for	example	the	change	of	dose	of	paracetamol	in	children,	a	product	
many	people	declared	their	confidence	in	using	due	their	long	experience	with	this	product.	
Similar	to	information-gathering,	a	move	to	self-selection	may	result	in	reduced	
opportunities	to	interact	with	people	and	will	place	the	individual	in	the	driving	seat	to	seek	
information	and	advice,	which	is	something	that	should	be	encouraged.		
Referral		
The	need	to	refer	people	in	an	appropriate	and	timely	manner	to	a	more	suitable	health	
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care	provider	such	as	the	GP,	as	identified	in	the	review,	further	strengthens	the	case	for	
needing	meaningful	interactions	to	happen	between	people	and	pharmacy	staff	for	treating	
minor	ailments	with	NPMs.	As	this	review	shows,	people	do	not	necessarily	correctly	recall	
advice	to	see	for	instance	the	GP18	but	also	even	when	they	have	grasped	this	piece	of	
advice	they	do	not	necessarily	act	on	it.18,49,70	Once	again	the	issue	of	pharmacy	staff	
needing	to	clearly	communicate	with	people	(with	repetition)	the	reason	for	referral	must	
be	stressed.	It	may	even	be	prudent	for	urgent	referrals	instigated	by	pharmacy	staff	to	be	
followed	up	by	the	pharmacist.		
Symptom	response	versus	direct	product	request		
Consultations	for	symptom	response	are	dealt	with	more	effectively	than	direct	product	
requests.37,38,65,84,91	This	is	partly	due	to	the	fact	that	people	making	a	direct	product	
request	know	what	they	want	and	staff	appear	to	feel	uncomfortable	to	exercise	unsolicited	
questions	and	to	provide	unsolicited	advice.	This	strongly	supports	the	findings	in	this	
review	that	indicate	that	the	success	of	consultations	and	facilitation	of	appropriate	sales	is	
dependent	and	is	better	effected	when	people	are	engaged	in	all	aspects	of	the	
consultation.	This	includes	people	knowing	and	being	willing	to	engage	the	pharmacy	team	
when	they	have	the	ability	to	self-select	a	product.	More	awareness	than	this	can	help	staff	
recognize	the	challenge	but	perhaps	training	for	dealing	with	NPMs	requires	two	models	of	
consultation	styles	or	protocols	rather	than	the	usual	focus	on	attempting	to	cover	a	set	of	
questions	and	deliver	advice	and	information,	but	rather	have	one	model	for	responding	to	
symptoms	and	one	for	direct	product	request,	this	focus	has	already	been	adopted	by	some	
pharmacy	chains.		
Pharmacists	and	non-pharmacist	staff	make	a	number	of	key	contributions	that	would	be	
unlikely	to	happen	if	medicines	moved	to	self-selection,	and	this	may	lead	to	delayed	
diagnoses	and	delayed	referrals.	Delays67	in	giving	advice	and	information	which	has	been	
shown	can	have	a	positive	effect	on	consumer	outcome	as	well	as	identifying	and	resolving	
drug	related	problems	included	drug	misuse/abuse.	If	P	medicines	are	to	be	made	available	
for	self-selection,	processes	to	ensure	that	patients	receive	a	pharmacist's	intervention	
when	appropriate	will	need	to	be	considered.		
It	is	important	that	Pharmacist	and	non-pharmacist	staff	improve	and	maintain	their	skills	in	
responding	to	people's	symptoms	and	product	selection	for	NPMs	as	product	availability	
and	advice	changes.61	Regular	training	is	needed	on	newly	deregulated	products	and	
changes	in	product	advice.	Very	little	time	appeared	to	be	dedicated	to	training	non-
pharmacist	staff.15,75		
Interventions	to	improve	consultations	for	NPMs		
Opportunities	to	capitalize	on	interventions	that	have	shown	promise	in	improving	
consultations	for	NPMs	should	be	sought	for	example,	targeted	training	and	quality	
improvement	initiatives	such	as	those	employed	in	Australia53	and	piloted	in	Scotland66	are	
needed	to	further	develop	pharmacists'	skills	to	ensure	the	appropriate	supply	of	P	
medicines.	Many	of	the	studies	did	not	distinguish	between	pharmacy	staff	and	
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pharmacists;	however,	in	the	UK	pharmacists	do	have	the	ultimate	responsibility	for	sale	of	
P	medicines,	and	it	is	important	that	they	can	intervene	in	sales	and	be	available	to	advice	
and	answer	patient	questions.		
Strengths	and	limitations		
Reviewing	studies	in	the	English	and	the	Dutch	language	may	have	narrowed	the	final	
number	of	studies	identified	for	the	review.		
Restricting	studies	to	those	conducted	in	the	UK	and	similar	countries	although	useful	for	
being	able	to	summarize	data	that	is	close	to	the	context	of	interest	i.e.	UK	may	have	
narrowed	the	opportunity	to	explore	how	NPMs	are	handled	in	different	contexts,	which	
would	benefit	the	pharmacy	team,	as	UK	is	a	multicultural	society,	and	customers	visiting	
pharmacies	may	have	in	fact	originated	from	settings	outside	the	UK.	Understanding	their	
context	may	have	helped	predict	their	response	or	behavior	if	proposal	to	make	medicines	
accessible	by	self-selection	is	realized.		
The	limitations	of	available	studies	investigating	the	role	of	the	pharmacist	specifically	
impacted	fulfilling	the	aim	of	the	study,	and	identifying	role	of	pharmacists	separate	from	
other	pharmacy	team	members	was	not	always	achievable.	The	decision	to	present	results	
for	community	pharmacy	staff	as	a	team	rather	than	focusing	solely	on	the	pharmacists	was	
necessitated	due	to	the	fact	that	pharmacy	staff	were	identified	frequently	as	making	
significant	contributions	to	consultations	for	NPM.	Additionally,	a	number	of	studies	did	not	
separate	out	the	contribution	of	the	pharmacist	from	other	staff,	making	it	impossible	to	
clearly	identify	what	unique	role	the	pharmacist	may	have	played.		
The	quality	of	a	consultation	for	an	NPM	is	a	multifaceted	concept	and	as	evident	from	this	
review	different	aspects	were	assessed	to	gauge	the	‘quality’	of	a	consultation.	Having	one	
measure	to	assess	quality	for	consultations	for	NPMs	would	make	assessment	of	quality	
more	manageable	however	this	is	an	unrealistic	expectation	as	community	pharmacies	as	a	
setting	are	a	multifaceted	health	setting	environment.		
Reviewing	studies	with	different	study	designs	added	to	the	complexity	of	summarizing	
findings,	solely	focusing	on	one	study	design	type	such	as	interventions	may	have	been	able	
to	give	a	clearer	picture	of	whether	quality	can	be	improved.	Nonetheless,	the	weakness	of	
this	study	is	also	a	strength	in	that	by	using	a	variety	of	study	designs	not	only	has	what	
actually	happens	in	consultations	has	been	able	to	be	captured	(e.g.	through	observation	
studies)	but	also	what	pharmacy	staff	and	customers	perceive	happen,	perceptions	may	
influence	the	behavior	of	how	both	pharmacy	staff	and	customers	interact	in	a	consultation	
for	an	NPM.	New	studies	need	to	be	commissioned	to	generate	a	more	homogenous	body	
of	evidence.		
Conclusion		
The	primary	aim	of	this	systematic	review	was	to	identify	and	summarize	the	available	
evidence	of	the	role	pharmacists	play	in	maintaining	and	guaranteeing	patient	safety,	
minimizing	abuse	of	NPMs	and	improving	the	quality	of	consultations	for	supply	of	P	
medicines,	and	to	establish	whether	or	not	the	intervention	of	a	pharmacist	is	important	in	
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the	sale	of	P	medicines	in	community	pharmacies.	If	pharmacy	staff	lack	the	competence	to	
carry	out	effective	NPM	consultations,	the	rationale	for	keeping	NPMs	behind	the	counter	is	
somewhat	unfounded.	However,	the	positive	contribution	made	by	pharmacy	staff	in	the	
supply	(or,	refusal	of	supply)	of	NPMs	cannot	be	entirely	ignored,	so	continued	efforts	to	
enhance	this	service	even	in	its	current	model	should	to	be	supported.	Whether	self-
selection	becomes	a	reality	in	UK	pharmacies,	there	still	appears	to	be	a	need	to	up-skill	
pharmacy	staff	so	that	consultations	for	NPMs	are	of	better	quality.		
The	important	role	that	customers	play	in	enabling	successful	consultations	for	NPMs	
should	not	be	underestimated.	Seeking	opportunities	to	communicate	with	customers	that	
pharmacy	staff	rely	on	there	being	a	minimal	level	of	information	exchange	for	appropriate	
and	safe	supply	of	NPMs	to	happen,	may	result	in	a	more	positive	view	amongst	people	to	
unsolicited	questioning	and	information/advice	giving	from	staff.	An	important	
consideration	for	pharmacy	owners	and	organizations	is	therefore	the	provision	of	a	
conducive	environment	for	optimal	information	exchange	to	occur,	where	staff	levels,	time	
and	space	are	adequate.		
This	review	was	based	on	83	papers,	with	many	different	study	designs	and	methods	of	
measuring	outcomes,	thus	making	comparisons	difficult.	The	pharmacist	and	their	staff	have	
so	many	different	roles	and	use	a	number	of	different	skills	in	the	process	of	supply	of	
NPMs,	and	not	everything	can	be	rigidly	defined.	To	overcome	these	problems,	larger	
studies	should	be	commissioned	to	generate	a	more	homogenous	body	of	evidence.		
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